Tag: big pharma

Pfizer’s election meddling exposed: Top scientists weaponized science to sway the 2020 vote, so they could benefit from unlawful mandates

In the high-stakes world of corporate power and political manipulation, few revelations strike as deeply as the allegation that Pfizer executives deliberately slowed COVID-19 vaccine trials to influence the 2020 U.S. election. Newly uncovered testimony suggests that top Pfizer R&D leaders orchestrated a delay in clinical testing—not for scientific caution, but to ensure results wouldn’t emerge before Election Day. This bombshell, revealed through congressional investigations, paints a damning picture of a pharmaceutical giant willing to play god with public health for political and financial gain. The implications are staggering: a company entrusted with saving lives instead weaponized its science, suppressed critical data, and helped shape an election that led to unprecedented medical coercion.

Key points:

  • Congressional investigators allege Pfizer intentionally slowed vaccine trials to avoid influencing the 2020 election.
  • Former Pfizer scientist Dr. Philip Dormitzer reportedly admitted the delay was orchestrated by senior R&D leaders.
  • The timing allowed Pfizer to avoid scrutiny before the election, then rapidly deploy mandates under a new administration.
  • The scheme backfired as vaccine failures and injuries mounted, exposing the fraud behind the rushed approvals.
  • The investigation raises urgent questions about corporate collusion, government corruption, and the erosion of medical ethics.

The election interference playbook

The 2020 presidential race was already one of the most contentious in U.S. history, with COVID-19 lockdowns, mask mandates, and promises of a “miracle” vaccine dominating the national conversation. Internal documents and whistleblower testimony now suggest Pfizer executives saw an opportunity—not to serve public health, but to exploit it. According to GSK’s testimony to Congress, Dr. Philip Dormitzer, a former Pfizer R&D leader, revealed that the company’s top three scientists deliberately slowed trial progress to avoid releasing data before November.

Dr. Dormitzer had told GSK employees that “in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year.”

This wasn’t about scientific rigor—it was about political timing. Had Pfizer released results in October, then-President Donald Trump could have claimed credit for Operation Warp Speed, potentially swaying voters eager for an end to pandemic restrictions. Instead, Pfizer’s calculated delay left the public in limbo, fueling frustration and anger that Democrats weaponized against Trump. By the time the vaccine was unveiled under the Biden administration, the groundwork had been laid for aggressive mandates, despite mounting evidence of the shot’s inefficacy and risks.

Keep reading

FDA Says It Plans to Remove Some Fluoride Drugs for Children From Market

The Food and Drug Administration (FDA) plans to remove ingestible prescription drugs for children that contain fluoride, the agency announced on May 13.

The ingestible products have been linked to issues such as a disrupted gut microbiome.

“The best way to prevent cavities in children is by avoiding excessive sugar intake and good dental hygiene, not by altering a child’s microbiome. For the same reason that fluoride may kill bacteria on teeth, it may also kill intestinal bacteria important for a child’s health,” Dr. Marty Makary, commissioner of the FDA, said in a statement.

Researchers reported in a review article in March that multiple studies have found that the gut microbiota was negatively impacted in people who ingested high amounts of fluoride, a disruption that can lead to problems such as cancer.

The FDA said it plans to complete a safety review by Oct. 31 before “taking appropriate action regarding removal of these products from the market.” At the same time, its parent agency, the Department of Health and Human Services, is planning to provide the public with guidance on strong dental hygiene for children that does not alter gut health.

“Ending the use of ingestible fluoride is long overdue,” Health Secretary Robert F. Kennedy Jr. said in a statement. “I’m grateful to Commissioner Makary for his leadership on this vital issue—one that directly safeguards the health and development of our children.”

Keep reading

Meet the Latest Vaccine Propagandist

On January 05, 2024, this Pharma Propaganda outlet published a video interview with Dr. Paul Offit, professional academic pediatrician and vaccine shill, in which he states a series of falsehoods in continuation of the gaslighting and falsehoods which both he and Dr. Peter Marks (FDA/CBER) are becoming known for.

Lets take a look at the transcript of this series of falsehoods.

First off, starting with the title, is Paul Offit actually a vaccine expert? What have his contributions actually been? Well, he self-identifies as the co-inventor of a licensed rotavirus vaccine (one of many, and not the first), and has received significant royalties from that. I should say currently licensed rotavirus vaccine, because there was a prior rotavirus vaccine (RotaShield – Wyeth) which was associated with an intolerable level of a clinical syndrome called “intussusception.”

If you know horses, you can think of intussusception as sort of like colic, but most often happening in children. More precisely, intussusception is a condition in which one segment of intestine “telescopes” inside of another, causing an intestinal obstruction (blockage). For some reason, rotavirus vaccines are associated with intussusception. It can be life threatening. The previously licensed rotavirus vaccine had a slightly higher rate of intussusception than the current one associated with Dr. Paul Offit (and Dr. H. Fred Clark, the senior of the two researchers).

This essay details the events surrounding the RotaShield withdrawal, including the role of Offit when participating in the Advisory Committee on Immunization Practices at the CDC. Basically, all US children are required to take either Offit’s vaccine or a competing similar live attenuated virus product. According to the CDC:

There is also a small risk of intussusception from rotavirus vaccination, usually within a week after the first or second dose. This additional risk is estimated to range from about 1 in 20,000 to 1 in 100,000 US infants who get rotavirus vaccine.

There are about 3.66 million births per year in the US, so that means between 36 to 180 cases of life-threatening intussusception in the US per year due to mandated administration of this product.

Keep reading

RFK Jr: “Pediatricians who vaccinate 80-85% of the kids in their office, get these GIANT bonuses!”

This is perhaps the most important — and most dangerous — article I have ever posted.

But I have to print the truth wherever I find it.

Let’s start with this clip from RFK Jr. explaining how pediatricians are given an incentive to vaccine your children with ALL the vaccines produced by Big Pharma…

So to summarize what he just said, he claims that pediatricians are given a monetary payout — a BONUS — if they vaccinate a high rate of children in their clinic.

He claims it can be as high as $400/child….

But ONLY IF they maintain high levels of vaccination overall at the clinic.

Which is why they freak out on you if you refuse to get the vaccines or don’t want to follow the CDC schedule.

It’s not hard to imagine in this scenario where they start to see each little kid with a dollar sign over their heads instead of a patient!

RFK Jr. explains how the business model is to increase traffic into the clinic.

Unlike when we were kids, and you only went to the doctor if you got hurt, now you go all the time!

Why?

“BUSINESS MODEL”.

Keep reading

Pharma-Friendly Public Health Officials Launch New Project to ‘Shore Up U.S. Vaccination Policy’

A group of public health figures has launched a new project they hope will “shore up U.S. vaccination policy,” which they believe is under threat from U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.

The “Vaccine Integrity Project,” launched Thursday, is funded by iAlumbra, a nonprofit founded by Walmart heiress and philanthropist Christy Walton. It will be based at the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP).

Michael Osterholm, Ph.D., CIDRAP director and a member of the COVID-19 Advisory Board under the Biden administration, said the project “acknowledges the unfortunate reality that the system that we’ve relied on to make vaccine recommendations and to review safety and effectiveness data faces threats.”

Former U.S. Food and Drug Administration (FDA) Commissioner Margaret Hamburg and Dr. Harvey Fineberg, former president of the Institute of Medicine and current president of the Gordon and Betty Moore Foundation, will co-chair an eight-member steering committee leading the initiative.

The group behind the project cited “a growing chorus of voices” in the U.S. questioning the safety and efficacy of vaccines as one of the inspirations for launching the project, Fierce Biotech reported.

In an op-ed published in STAT News, Hamburg and Fineberg said the project will use “the best available evidence” to “safeguard vaccine policy, information and utilization.”

The project will hold information-gathering sessions with public health stakeholders and share its recommendations with “nongovernment entities … that are free of outside influence and focus on protecting Americans from vaccine-preventable diseases.”

According to a press release, the project’s recommendations will be “grounded in the best available science.”

Keep reading

FDA Removing Pharmaceutical Representatives From Advisory Panels

The Food and Drug Administration (FDA) is removing pharmaceutical company representatives from advisory committees in a bid to limit industry influence.

Dr. Marty Makary, the FDA’s new commissioner, issued a directive that eliminates the role of pharmaceutical representative

“Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official members of FDA advisory committee members represents a cozy relationship that is concerning to many Americans,” Makary said in a statement on April 17. “In fact, the FDA has a history of being influenced unduly by corporate interests.”

The FDA has 32 different advisory committees, including panels that advise the agency on vaccines, food, and medical devices. Members are primarily a mix of federal employees and experts who do not work for industries.

But each FDA committee has an industry representative and an alternate industry representative. The Vaccine and Related Biological Products Advisory Committee, for instance, had a Pfizer officer and a Dynavax officer listed on the roster for its most recent meeting.

The industry representatives do not vote on what advice to convey to the FDA, but “offer perspective of a pharmaceutical company,” Kim Witczak, who has served on several FDA advisory committees, told The Epoch Times in an email.

“Sometimes they will say something that could influence or sway the discussion. I always wondered why they were on the committee,” she said.

Keep reading

Mental Health “Experts” FEAR Secretary Kennedy’s Investigation into Psychiatric Drugging

Within a few weeks of Donald Trump’s inauguration, the President signed an Executive Order establishing the Make America Healthy Again Commission (MAHA), which, among other things, will be “assessing the prevalence of and threat posed by the prescription of Selective Serotonin Reuptake Inhibitors (SSRIs), antipsychotics, mood stabilizers, stimulants and weight-loss drugs.” In other words, officialdom finally is looking at the out-of-control unscientific chemical experimentation used to address unwanted behaviors.

Alert the media! Get Megyn Kelly on the phone! Finally, a governmental body will be looking into the serious risks associated with prescription mind-altering drugs. It’s decades in the making. But, as they say, “better late than never.” It was no surprise then that within a month of that announcement the mental health industry was none too pleased and released a “joint statement” about the wonders of its mind-altering chemical elixirs.

According to the statement, “these drugs provide relief for many young people enabling them to participate fully in treatment, school, social activities, and family life — all key aspects of healthy development.” Utter nonsense.

“Healthy development?” There is no such thing as the decades-long touted “chemical imbalance.” That theory finally got debunked in 2022 research published by Professor Joanna Moncrieff and Dr. Mark Horowitz. So, since it’s clear that people are not “short” on certain brain chemicals as a reason for depression, then why are those chemicals being prescribed as “treatment?” And, make no mistake, lots and lots of Americans are being drugged.

According to data gathered in 2020 by IQVIA (Formerly IMS Health) and made public by the Citizens Commission on Human Rights (CCHR) in January of 2021, nearly 77 million Americans are taking at least one prescription psychiatric drug. The breakdown of who is drugged is jaw dropping crazy. There were more than 85 thousand 0–1-year-olds, nearly 140,000 2–3-year-olds, 215,000 4- to five-year-olds, two-and-a-half million 6–12-year-olds and more than three million 13–17-year-olds taking psychiatric mind-altering drugs every day.

Keep reading

Fired FDA Chief Is Now Out Trashing RFK Jr. and his Autism Study on the Fake News – Big Pharma Has Most to Lose

Dr. Peter Marks, the FDA’s top vaccine official and a key figure in the first Trump administration’s Operation Warp Speed, was ousted from his post earlier this month.

​Dr. Peter Marks is an American hematologist-oncologist who has served as the director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) since 2016.

As CBER director, Marks was responsible for reviewing and providing advice during product development, evaluating applications, and making approval decisions based on safety and effectiveness data.

He oversaw the FDA’s vaccine programs and played a pivotal part in the rapid development and approval of the experimental COVID-19 vaccines under Operation Warp Speed during President Donald Trump’s first term.

Sources close to the matter told the Wall Street Journal that Marks submitted his resignation on Friday after a blunt ultimatum from a Health and Human Services (HHS) official: step down voluntarily or face termination.

His exit, effective April 5, marks yet another victory for HHS Secretary Robert F. Kennedy Jr.’s aggressive push to purge the federal health apparatus of what he calls entrenched bureaucrats peddling “misinformation and lies.”

It was very telling that Big Pharma stocks plunged following his resignation.

Shares of vaccine makers Moderna and Novavax, along with several other biotech companies, plunged following his resignation.

Now, Marks is out hitting the Sunday shows and attacking Robert Kennedy Jr.  It makes you wonder who is behind this?

The Disgraced former FDA official is ALREADY defending Big Pharma from RFK Jr’s groundbreaking study on autism.

This is how committed the Big Money players are with keeping the vaccines flowing no matter how many Americans will be injured or killed.

Keep reading

Trump Admin Launches National Security Probe Into Pharma, Semiconductor Imports

The Trump administration has launched an investigation into the effects on national security of importing semiconductors and pharmaceutical products, according to Federal Register filings on Monday.

The Commerce Department, in a pair of Federal Register notices set to be published on April 16, said that the probes were initiated under Section 232 of the Trade Expansion Act—which allows the president to impose tariffs on imports considered a threat to national security.

The department stated that it began investigating the national security implications of importing semiconductors and semiconductor manufacturing equipment (SME) on April 1.

This includes “semiconductor substrates and bare wafers, legacy chips, leading-edge chips, microelectronics, and SME components,” as well as derivative products of those items, according to one of the filings.

The probe will assess current and projected demand for semiconductors and SME in the United States; the extent to which domestic production can or is expected to meet that demand; the role of foreign fabrication and assembly; the concentration of U.S. semiconductor imports; and the potential for export restrictions by other nations; among other issues.

In another notice, the department said it was investigating imports of pharmaceuticals and their ingredients. This includes “finished generic and non-generic drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients and key starting materials, and derivative products of those items.”

Keep reading

FDA Says It Plans to Phase out Animal Testing for Drug Development

The Food and Drug Administration (FDA) on April 10 said it will be phasing out animal testing for monoclonal antibodies and other drugs.

FDA officials said that its animal testing requirement will be “reduced, refined, or potentially replaced” with other approaches, including advanced computer simulations utilizing artificial intelligence and lab-grown products that are designed to mimic human organs.

The agency will also start looking at preexisting, real-world safety data from other countries that have regulatory standards similar to those in the United States.

“For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,” FDA Commissioner Dr. Marty Makary said in a statement.

He said that the move “represents a major step toward ending the use of laboratory animals in drug testing.”

Companies that submit what the agency described as strong safety data from non-animal testing could receive faster review, according to the FDA.

Keep reading